1.888.321.7828 sales@pepid.com

There’s a new drug for people suffering from Chronic Idiopathic Constipation(CIC) headed to the market in 2019. The US FDA has approved Motegrity with the active ingredient Prucalopride for the treatment of CIC presented by Shire Dev LLC. Motegrity is a selective serotonin 04 (5-HT4) receptor agonist, that works by enhancing colonic peristalsis to increase bowel motility as a once-daily oral treatment. Throughout five of six controlled clinical studies, Motegrity helped normalize complete spontaneous bowel movement frequency.

[elfsight_social_share_buttons id=”3″]


Share This